Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Onconetix (ONCO) Gains from Sales and Divestitures (2023 - 2024)

Historic Gains from Sales and Divestitures for Onconetix (ONCO) over the last 2 years, with Q4 2024 value amounting to $688308.0.

  • Onconetix's Gains from Sales and Divestitures rose 1091292.8% to $688308.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $688308.0, marking a year-over-year increase of 1091292.8%. This contributed to the annual value of $688308.0 for FY2024, which is 1091292.8% up from last year.
  • Onconetix's Gains from Sales and Divestitures amounted to $688308.0 in Q4 2024, which was up 1091292.8% from $4852.0 recorded in Q3 2024.
  • Over the past 5 years, Onconetix's Gains from Sales and Divestitures peaked at $688308.0 during Q4 2024, and registered a low of $4852.0 during Q3 2024.